Select Publications
Conference Abstracts
, 2025, 'INTERROGATE-GBM Phase I trial: Immunotherapy peptide vaccine targeting cytomegalovirus (CMV) antigens in glioblastoma', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 27, pp. v425 - v425, http://dx.doi.org/10.1093/neuonc/noaf201.1679
, 2025, 'Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 27, pp. v243 - v244, http://dx.doi.org/10.1093/neuonc/noaf201.0970
, 2025, 'Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 27, pp. v423 - v424, http://dx.doi.org/10.1093/neuonc/noaf201.1676
, 2025, 'Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study', in ANNALS OF ONCOLOGY, ELSEVIER, Vol. 36, http://dx.doi.org/10.1016/j.annonc.2025.08.540
, 2025, 'Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004
, 2025, 'Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG plus )', in ANNALS OF ONCOLOGY, ELSEVIER, Vol. 36, http://dx.doi.org/10.1016/j.annonc.2025.08.1767
, 2024, 'GENOME-WIDE DNA METHYLATION PATTERNS IN PERIPHERAL BLOOD OF PATIENTS WITH GLIOBLASTOMA ENROLLED ON THE PHASE II VERTU TRIAL', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, TX, Houston, Vol. 26, presented at 29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), TX, Houston, 21 November 2024 - 24 November 2024, http://dx.doi.org/10.1093/neuonc/noae165.0138
, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', in Journal of Clinical Oncology, Vol. 42, pp. 4 - 4, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.4
, 2022, 'Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11570
, 2021, 'A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: The VERTU study', in Neuro Oncology, Vol. 23, pp. 1736 - 1749, http://dx.doi.org/10.1093/neuonc/noab111
, 2020, 'PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, ELECTR NETWORK, Vol. 22, pp. 179 - 180, presented at 25th Virtual Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), ELECTR NETWORK, 19 November 2020 - 21 November 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000590061300749&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2011